Antibiotic resistance in the intensive care unit

Annals of Internal Medicine

Volumn 134, Issue 4, 2001, Pages 298-314

  Kollef, M H ^a   Fraser, V J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL COLONIZATION; DISEASE ACTIVITY; HEALTH CARE COST; HOSPITAL INFECTION; HYGIENE; INFECTION CONTROL; INFECTION RISK; INTENSIVE CARE UNIT; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; TREATMENT PLANNING;

EID: 0035916299     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-134-4-200102200-00014     Document Type: Review

References (203)

1. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership
2. Antimicrobial resistance: An overview
3. New resistance in Staphylococcus aureus
4. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study; EPIC International Advisory Committee
5. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries
6. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection
7. Emergence of vancomycin resistance in Staphylococcus aureus
8. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens
9. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals
10. Antimicrobial-drug resistance
11. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit
12. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp from intensive care units in Europe
13. The role of understaffing and overcrowding in recurrent outbreaks of staphylococcal infection in a neonatal special-care unit
14. Antibiotic resistance in hospital bacteria: Current patterns, modes for appearance or spread, and economic impact
15. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture technique
16. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients
17. Three-year multicenter surveillance of systemic pneumococcal infections in children
18. Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection
19. Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients
20. Impact of previous anti microbial therapy on the etiology and outcome of ventilator-associated pneumonia
21. Ventilator-associated pneumonia: A multivariate analysis
22. The effect of late-onset ventilator-associated pneumonia in determining patient mortality
23. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella
24. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins
25. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus
26. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria
27. External sources of vancomycin-resistant enterococci for intensive care units
28. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System
29. The impact of nosocomial infections on patient outcomes following cardiac surgery
30. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes
31. Bacterial colonization of nursing home residents on admission to an acute care hospital
32. Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive-care unit defined by restriction fragment-length polymorphism typing
33. An outbreak of Burkholderia cepacia lower respiratory tract infection associated with contaminated albuterol nebulization solution
34. The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia
35. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia
36. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit
37. The value of routine microbial investigation in ventilator-associated pneumonia
38. Antimicrobial therapy of ventilator-associated pneumonia. How to select an appropriate drug regimen
39. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients
40. Staphylococcus aureus: A well-armed pathogen
41. Arthritis and sepsis caused by Staphylococcus aureus: Can the tissue injury be reduced by modulating the host's immune response?
42. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes
43. Resistance to methicillin and virulence of Staphylococcus aureus strains in bacteremic cancer patients
44. Cell-to-cell signaling and Pseudomonas aeruginosa infections
45. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia
46. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay
47. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient
48. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection
49. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: A case-control and molecular epidemiologic investigation
50. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults
51. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes
52. Comparative study of bacteremias caused by Enterococcus spp. with and without high-level resistance to gentamicin
53. Analysis of 1186 episodes of gram-negative bacteremia in non-university hospitals: The effects of antimicrobial therapy
54. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy
55. Enterococcal bacteremia in the surgical intensive care unit. Does vancomycin resistance affect mortality?
56. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: Comparison of clinical features and outcomes
57. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: Impact of intravascular devices and methicillin resistance
58. Consequences of bacterial resistance to antibiotics in medical practice
59. Epidemiology of drug resistance: Implications for a post-antimicrobial era
60. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa
61. Health and economic impact of antimicrobial resistance
62. Bug-drug resistance: Sometimes less is more
63. A novel antimicrobial agent joins the battle against resistant bacteria
64. The role of fundamental research and biotechnology in finding solutions to the global problem of antibiotic resistance
65. Antibiotic resistance: A view from the pharmaceutical industry
66. The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance
67. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality
68. Improving empiric antibiotic selection using computer decision support
69. Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes
70. A computer-assisted management program for antibiotics and other antiinfective agents
71. Changing the infection control paradigm from off-line to real time: The experience at Millard Fillmore Health System
72. Improving empirical antibiotic treatment: Prospective, nonintervention testing of a decision support system
73. Major change in the use of antibiotics following a national programme: Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and Surveillance of Resistance (STRAMA)
74. New intervention strategies for reducing antibiotic resistance
75. The effect of monitoring of antibiotic use on decreasing antibiotic resistance in the hospital
76. Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficile-associated diarrhea and cost
77. Experience with a hospital-wide outbreak of vancomycin-resistant enterococci
78. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions
79. Decreasing antibiotic use in ambulatory practice: Impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults
80. Improving the quality of antibiotic prescription patterns in general practice
81. Mechanism of action and impact of a cystitis clinical practice guideline on outcomes and costs of care in an HMO
82. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland
83. The potential for clinical guidelines to impact appropriate antimicrobial agent use
84. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci
85. Cefrazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veteran Affairs Medical Center
86. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia
87. New uses for older antibiotics. The 'rediscovery' of four beneficial and cost-effective antimicrobials
88. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia
89. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy
90. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial
91. Short course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription
92. Using bronchoalveolar lavage to distinguish nosocomial pneumonia from systemic inflammatory response syndrome: A prospective analysis
93. Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients
94. Antibiotic resistance patterns among blood culture isolates in a Danish county 1981-1995
95. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: A multicenter, randomized controlled trial
96. Impact of infectious disease specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia
97. Implementation of consensus guidelines for the follow-up of positive blood cultures
98. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting
99. Aminoglycoside resistance and aminoglycoside usage: Ten years of experience in one hospital
100. Scheduled rotation of antibiotic classes. A strategy to decrease the incidence of ventilator-associated pneumonia due to antibiotic-resistant gram-negative bacteria
101. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices
102. A pilot study of antibiotic cycling in a hematology-oncology unit
103. Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria
104. Variations in etiology of ventilator-associated pneumonia across four treatment sites
105. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection
106. A protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma
107. Intestinal decontamination for control of nosocomial multiresistant gram-negative bacilli. Study of an outbreak in an intensive care unit
108. Long-term effects of selective decontamination on antimicrobial resistance
109. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit
110. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control
111. Intermittent bolus dosing of cefrazidime in critically ill patients
112. The importance of antibiotic pharmacokinetics in critical illness
113. The future - Can we learn from the past?
114. Changing attitudes to infection management in primary care: A controlled trial of active versus passive guideline implementation strategies
115. Using a practice guideline for safely shortening hospital stay for upper gastrointestinal tract hemorrhage
116. Use of guidelines in primary care - Practitioners' perspectives
117. Prospective evaluation of a clinical guideline recommending hospital length of stay in upper gastrointestinal tract hemorrhage
118. Cooperation: The foundation of improvement
119. Prospective surveillance of imipenem/cilastin use and associated seizures using a hospital information system
120. Antibiotic-resistance - Squeezing the balloon?
121. Does antibiotic restriction prevent resistance?
122. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures
123. A comparative analysis of patients with early-onset versus late-onset nosocomial pneumonia (NP) in the ICU setting
124. Treatment and prevention of nosocomial pneumonia
125. Pseudomonas aeruginosa bacteremia: An analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy
126. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: A prospective, observational study
127. Trends in antibiotic utilization and bacterial resistance: Report of the National Nosocomial Resistance Surveillance Group
128. Evaluating treatment protocols to prevent antibiotic resistance
129. Circumventing antibiotic resistance in specialized hospital units
130. Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU?
131. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement
132. Community-acquired pneumonia in adults - Guidelines for management
133. Epidemiological analysis defining concurrent outbreaks of Serratia marcescens and methicillin-resistant Staphylococcus aureus in a neonatal intensive-care unit
134. Effectiveness of antibiotic prophylaxis in critically ill adult patients; systematic review of randomized controlled trials
135. Selective decontamination of the digestive tract in surgical patients. A systematic review of the evidence
136. Continuous improvement as an idea in healthcare
137. Utilizing quality assurance as a tool for reducing the risk of nosocomial ventilator-associated pneumonia
138. An effective continuous quality improvement approach to the prevention of ventilator-associated pneumonia
139. Cost-effective application of the Centers for Disease Control Guideline for Prevention of Nosocomial Pneumonia
140. Improving hospital-acquired infection rates: The CDC experience
141. Central venous catheter-related bacteremia in critically ill neonates: Risk factors and impact of a prevention programme
142. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus
143. Preventing nosocomial pneumonia; state of the art and perspectives for the 1990s
144. Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial
145. A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure
146. Does noninvasive ventilation reduce the ICU nosocomial infection risk?. A prospective clinical survey
147. Avoidance of tracheal intubation as a strategy to prevent ventilator-associated pneumonia
148. A randomized, controlled trial of protocol-directed versus physician-directed weaning from mechanical ventilation
149. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously
150. Artificial nutrition after major abdominal surgery: Impact of route of administration and composition of the diet
151. Nutritional support and infection: Does the route matter?
152. Prevention of infections caused by central venous catheters established and novel measures
153. Prevention of central venous catheter-related infection
154. Infectious complications of Swan-Ganz pulmonary artery catheters. Pathogenesis, epidemiology, prevention and management
155. Prevention of peripheral venous catheter complications with an intravenous therapy team: A randomized controlled trial
156. Impact of an educational program for prevention of colonization of intravascular catheters
157. Prevention of catheter-related infections: The skin
158. A comparison of two antimicrobial-impregnated central venous catheters
159. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: A meta-analysis
160. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection
161. Catheter-associated infections in urology: Possible use of silver-impregnated catheters and the Erlanger silver catheter
162. Plasmids and bacterial resistance to biocides
163. The decline of Haemophilus influenzae type b disease in Australia
164. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: A randomized controlled trial
165. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention
166. Safety and immunogenicity of Pseudomonas aeruginosa hybrid outer membrane protein F-1 vaccine in human volunteers
167. Broadly protective vaccine for Staphylococcus aureus based on an in-vivo expressed antigen
168. Nosocomial respiratory infections with gram-negative bacilli: The significance of colonization of the respiratory tract
169. Staphylococcus aureus; the persistent pathogen
170. The role of colonization in the pathogenesis of nosocomial infections
171. Handwashing - The Semmelweis lesson forgotten?
172. Hand-washing and nosocomial infections
173. Vancomycin-resistant enterococci in intensive-care hospital settings: Transmission dynamics, persistence, and the impact of infection control programs
174. Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units
175. Patient density, nurse-to-patient ratio and nosocomial infection risk in a pediatric cardiac intensive care unit
176. The role of understaffing in central venous catheter-associated bloodstream infections
177. Compliance with handwashing in a teaching hospital
178. Outbreak of Enterobacter cloacae related to understaffing, overcrowding, and poor hygiene practices
179. Handwashing with soap or alcoholic solutions?. A randomized clinical trial of its effectiveness
180. No time for handwashing? Handwashing versus alcoholic tub: Can we afford 100% compliance?
181. Patient educational model for increasing handwashing compliance
182. Increasing ICU staff handwashing: Effects of education and group feedback
183. Skin hygiene and infection prevention: More of the same or different approaches?
184. Influence of the quality of nursing on the duration of weaning from mechanical ventilation in patients with chronic obstructive pulmonary disease
185. Housestaff workload and procedure frequency in the neonatal intensive care unit
186. Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery
187. Winning the battle but losing the war: Methicillin-resistant Staphylococcus aureus (MRSA) infection at a teaching hospital
188. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit
189. Control of methicillin-resistant Staphylococcus aureus in a hospital and an intensive care unit
190. Reduction of nosocomial infection during pediatric intensive care by protective isolation
191. Nosocomial infection following cardiovascular surgery: Comparison of two periods, 1987 vs. 1992
192. Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions
193. Total and attributable costs of surgical-wound infections at a Canadian tertiary-care center
194. Prolonged use of ventilator circuits and ventilator-associated pneumonia: A model for identifying the optimal clinical practice
195. Mechanical ventilation with or without daily changes of in-line suction catheters
196. Requirements for infrastructure and essential activities of infection control and epidemiology in hospitals: A consensus panel report
197. Antibiotic optimization. An evaluation of patient safety and economic outcomes
198. Implications of endotracheal tube biofilm for ventilator-associated pneumonia
199. Protegrin-1: A broad-spectrum, rapidly microbicidal peptide with in vivo activity
200. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients
201. Pseudomonas aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and virulence in a mouse model of acute pneumonia
202. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systematic vaccination